Novartis Healthcare Philippines, Inc. incorporated in 1996 is one of the leading research-based pharmaceutical companies in the country, providing innovative, life-saving medicines to patients.
Novartis has made substantial contributions to support the Philippine economy and improve health outcomes of Filipinos:
The company has opened up more employment opportunities for Filipinos and is providing broader regional leadership exposure to local talents.
Novartis has been officially recognized by the Top Employers Institute as a Top Employer in the Philippines for three consecutive years (2021 - 2023). To become recognized as a Top Employer, an organization must demonstrate its commitment to putting its people first through its exceptional human resource (HR) policies. Top Employers Institute is the global authority on recognizing excellence in people practices.
DEIC is a global program that aims to accelerate innovation, growth, and performance by embedding diversity, equity, and inclusion within our culture. It focuses on enabling diverse talent, fostering belonging, closing the wellbeing gap, and enhancing employee experience and engagement.
In 2023, the full Novartis portfolio of medicines reached 1 million Filipino patients. Filipino patients who took Novartis medicines gained a total of 7,355 quality-adjusted life-year (QALYs). QALY is a generic measure of disease burden, including both the quality and the quantity of life lived. It is used in economic evaluation to assess the value of medical interventions. One QALY equates to one year in perfect health.
Novartis is committed to collaborative partnerships with key stakeholders that share our goal of strengthening the Philippine healthcare system.
Our partnerships leverage the collective strengths of the government, medical community, patient advocacy groups, private sector, academe, and civil society organizations.
With the Philippine Press Institute, ICanServe Foundation, Pharmaceutical and Healthcare Association of the Philippines, and the Alliance and Partnerships for Patient Innovations & Solutions (APPIS), we organized the “Health Reporting on Breast Cancer in the Philippines” virtual workshop to deepen local journalists’ understanding about breast cancer.
With the Philippine Cancer Society, ICanServe Foundation, Swiss Chamber of Commerce of the Philippines, and the Swiss Embassy, we held the “Inspiring Conversations on Breast Cancer in the Philippines”, a 5-part roundtable series which aimed to help meet the Global Breast Cancer Initiative targets and motivate stakeholders to support the full implementation of the National Integrated Cancer Control Act (NICCA).
With the Rizal Medical Center (RMC) and Thinking Machines Data Science, Inc., we launched STAHR, a web-based electronic referral solution for hospitals that supports the implementation of Health Care Provider Networks (HCPNs).
DISCLAIMER:
Novartis does not engage in the promotion of unregistered products or unapproved indications. Please consult local Prescribing Information for registration/product license details.
PH2403073790-31032026-NP